Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
fq2r8DKBQaJHF2Wg
